Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Cindy Delbrook"'
Autor:
Ling Zhang, Maryalice Stetler-Stevenson, David F. Stroncek, Daniel W. Lee, Cindy Delbrook, Terry J. Fry, Marianna Sabatino, Alan S. Wayne, Steven R. Feldman, Yongzhi Cui, Nirali N. Shah, Crystal L. Mackall, Constance M. Yuan, Nick Tschernia, Hua Zhang, James N. Kochenderfer, Steven A. Rosenberg, Bonnie Yates
Publikováno v:
Blood. 124:381-381
Relapsed or refractory acute lymphoblastic leukemia (ALL) remains a difficult therapeutic challenge. We developed a platform where T cells are collected, transduced via retrovirus with a chimeric antigen receptor (CAR) targeting CD19 and incorporatin
Autor:
Steven A. Rosenberg, James N. Kochenderfer, David F. Stroncek, Alan S. Wayne, Daniel W. Lee, Crystal L. Mackall, Nirali N. Shah, Maryalice Stetler-Stevenson, Cindy Delbrook, Marianna Sabatino, Kelly Richards
Publikováno v:
Blood. 122:68-68
Survival after relapsed and refractory pediatric pre-B ALL and non-Hodgkin lymphoma (NHL) is poor despite intensive chemotherapy and HSCT. CAR T cells combine the specificity and MHC independence of antibodies with the cytotoxic capacity of T cells.
Autor:
Marianna Sabatino, Alan S. Wayne, Steven A. Rosenberg, Cindy Delbrook, Daniel W. Lee, James N. Kochenderfer, Crystal L. Mackall, David F. Stroncek, Kelly Richards, Maryalice Stetler-Stevenson, Nirali N. Shah
Publikováno v:
Cancer Research. 73:LB-138
Introduction: Despite aggressive therapies such as HSCT, survival in relapsed and refractory pediatric ALL and NHL is poor. CAR modified T cells targeting CD19 have been effective in adult B-cell malignancies. These studies have employed T cells eith
Autor:
Marianna Sabatino, David F. Stroncek, Cindy Delbrook, Alan S. Wayne, Daniel W. Lee, Steven A. Rosenberg, Crystal L. Mackall, James N. Kochenderfer, Maryalice Stetler-Stevenson, Kelly Richards, Barbara Tumaini
Publikováno v:
Blood. 120:2609-2609
Abstract 2609 Children with relapsed or chemotherapy-refractory ALL have a poor prognosis despite the use of aggressive therapies such as HSCT. Chimeric antigen receptor modified T cells targeting the B-cell antigen CD19 have been reported to be effe